US 12,440,480 B2
Use of naphthylurea compound
Fei Zhang, Suzhou (CN); Sen Wang, Suzhou (CN); and Yanhong Zhang, Suzhou (CN)
Assigned to SUZHOU RAYMON PHARMACEUTICALS COMPANY, LTD., (CN)
Appl. No. 17/785,713
Filed by SUZHOU RAYMON PHARMACEUTICALS COMPANY, LTD., Suzhou (CN)
PCT Filed Dec. 16, 2019, PCT No. PCT/CN2019/125567
§ 371(c)(1), (2) Date Jun. 15, 2022,
PCT Pub. No. WO2021/119902, PCT Pub. Date Jun. 24, 2021.
Prior Publication US 2023/0062969 A1, Mar. 2, 2023
Int. Cl. A61K 31/437 (2006.01); A61K 31/416 (2006.01); A61P 27/02 (2006.01)
CPC A61K 31/437 (2013.01) [A61K 31/416 (2013.01); A61P 27/02 (2018.01)] 13 Claims
 
1. A method for treating a corneal neovascular disease in a patient in need thereof, comprising: administering an effective amount of a substance A to the patient wherein, the substance A is a naphthylurea compound as shown in formula V, a pharmaceutically acceptable salt thereof, a solvate thereof, a solvate of the pharmaceutically acceptable salt thereof, or a tautomer thereof;

OG Complex Work Unit Chemistry